Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Our vision is to become a leader in the nephrology and specialty care space by delivering innovative therapeutic offerings to patients and healthcare providers.
- June 13, 2014 Affymax and Takeda Announce Termination of Omontys®(peginesatide) Product Collaboration and License Agreement
- Jun 6, 2013 Affymax Announces Update on Listing, Senior Leadership and Board Changes
- Apr 2, 2013 Affymax Reports Fourth Quarter and Year-End 2012 Financial Results
Computershare Trust Company, Inc.
350 Indiana Street, Suite 800, Golden, Colorado 80401